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Abstract
Matrix metalloproteinase 9 (MMP9) is involved in the proteolysis of extracellular pro‐
teins and plays a critical role in pancreatic ductal adenocarcinoma (PDAC) progression, 
invasion and metastasis. The therapeutic potential of an anti‐MMP9 antibody (αMMP9) 
was evaluated in combination with nab‐paclitaxel (NPT)‐based standard cytotoxic ther‐
apy in pre‐clinical models of PDAC. Tumour progression and survival studies were per‐
formed in NOD/SCID mice. The mechanistic evaluation involved RNA‐Seq, Luminex, 
IHC and Immunoblot analyses of tumour samples. Median animal survival compared to 
controls was significantly increased after 2‐week therapy with NPT (59%), Gem (29%) 
and NPT+Gem (76%). Addition of αMMP9 antibody exhibited further extension in sur‐
vival: NPT+αMMP9 (76%), Gem+αMMP9 (47%) and NPT+Gem+αMMP9 (94%). Six‐week 
maintenance therapy revealed that median animal survival was significantly increased 
after NPT+Gem (186%) and further improved by the addition of αMMP9 antibody 
(218%). Qualitative assessment of mice exhibited that αMMP9 therapy led to a reduction 
in jaundice, bloody ascites and metastatic burden. Anti‐MMP9 antibody increased the 
levels of tumour‐associated IL‐28 (1.5‐fold) and decreased stromal markers (collagen I, 
αSMA) and the EMT marker vimentin. Subcutaneous tumours revealed low but detect‐
able levels of MMP9 in all therapy groups but no difference in MMP9 expression. Anti‐
MMP9 antibody monotherapy resulted in more gene expression changes in the mouse 
stroma compared to the human tumour compartment. These findings suggest that anti‐
MMP9 antibody can exert specific stroma‐directed effects that could be exploited in 
combination with currently used cytotoxics to improve clinical PDAC therapy.
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1  | INTRODUC TION
Pancreatic ductal adenocarcinoma (PDAC) is one of the most ag‐
gressive tumours and is characterized by extensive local invasion, 
metastasis to distant organs and high rate of treatment failure after 
both local and systemic therapies.1 Through its extremely poor 
prognosis, PDAC is estimated to become the second leading cause 
of cancer‐associated mortality by 2030.2 This dismal outcome in 
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PDAC is in part related to the absence of early diagnostic markers, 
aggressive progression pattern and lack of effective therapeutic op‐
tions. While surgical resection remains the only curative treatment 
option for PDAC, unfortunately, only 15%‐20% of patients are can‐
didates for resection, and most resected PDAC patients succumb 
to disease recurrence.3 Therefore, in recent years, much attention 
has been placed on improving systemic therapy options for PDAC. 
Gemcitabine (Gem), a nucleoside pyrimidine analogue, became 
the standard drug in PDAC after a positive clinical trial in 1997; it 
demonstrated a 5%‐10% response rate and a median overall survival 
of 6 months.4 FOLFIRINOX treatment, a combination of three che‐
motherapy drugs, nearly doubled the overall patient survival, but 
this regimen has higher toxicity risks.5 Nab‐paclitaxel (NPT) in com‐
bination with gemcitabine (Gem) is currently the most widely used 
chemotherapy regimen due to its favourable toxicity profile and me‐
dian overall survival 8.5 months.6 Due to these limitations of current 
regimens for clinical PDAC therapy, there is an urgent requirement 
for novel therapeutic strategies with better efficacy and less toxicity.
Matrix metalloproteinases (MMPs) are a family of zinc‐contain‐
ing enzymes that degrade extracellular matrix (ECM) components 
and play a crucial role in tumour invasion, metastasis and angio‐
genesis.7 MMPs comprise a large family of 23 members that can 
be subclassified into different groups mainly based on their sub‐
strate specificity and amino acid sequence including collagenases 
(MMP‐1, 8, 13), gelatinases (MMP‐2, 9), stromelysins (MMP‐3, 10, 
11), matrilysin (MMP‐7), metalloelastase (MMP‐12) and membrane‐
bound proteinases (MMP‐14, 15, 16).8 The activity of MMPs is 
tightly regulated by their endogenous inhibitors, the tissue inhibi‐
tors of metalloproteinase (TIMPs). MMP expression is up‐regulated 
in several solid tumours including pancreatic cancer and correlates 
with tumour invasiveness and metastatic potential.9,10 Several 
small molecule semi‐selective MMP inhibitors have been studied in 
different solid tumours including pancreatic cancer. A broad‐spec‐
trum MMP inhibitor BB‐94 demonstrated a significant antitumour 
response in pre‐clinical pancreatic cancer models.11 However, in 
clinical studies, the broad‐spectrum MMP inhibitors marimastat 
or tanomastat failed to show any significant clinical response.12,13 
The failure of the broad‐spectrum MMP9 inhibitors in clinical tri‐
als was mainly correlated with dose‐limiting side effects, a narrow 
therapeutic window as MMPs play a critical role in homeostatic 
processes 14 and general lack of efficacy in advanced tumour bur‐
den settings.15,16 Therefore, recently, the focus has been shifted 
towards more specific MMP inhibitors (such as MMP2 or 9 anti‐
bodies) that may have better efficacy and improved toxicity profile.
Matrix metalloproteinase 9 (MMP9) is one of the type IV colla‐
genases of the MMP family that is capable of cleaving a wide range 
of ECM components including gelatins, denatured collagens, elastin 
and laminin.17 MMP9 is involved in many developmental processes, 
including ECM degradation, angiogenesis and wound healing. 
Recently, MMP9 has also been shown to be involved in cell prolif‐
eration, migration, invasion and epithelial‐mesenchymal transition 
(EMT).18 MMP9 overexpression has been observed in many solid 
tumours, including pancreatic cancer, and is correlated with poor 
prognosis.19‐25 In the present study, we evaluated the therapeutic ef‐
ficacy of a highly selective and potent anti‐MMP9 antibody AB0046, 
the murine surrogate of humanized MMP9 antibody andecaliximab, 
in combination with nab‐paclitaxel‐based standard chemotherapy 
in pre‐clinical models of pancreatic cancer. Previous studies have 
shown the antitumour efficacy of AB0046 in pre‐clinical models of 
colorectal cancer 26 and encouraging clinical activity of andecalix‐
imab in combination with chemotherapy in gastric cancer.27
2  | MATERIAL S AND METHODS
2.1 | Cell culture and reagents
The human PDAC cell line AsPC‐1 was purchased from the American 
Type Culture Collection (ATCC, Rockville, MD) and had been tested 
and authenticated by ATCC. Characteristic genetic alterations in the 
AsPC‐1 cell line include KRAS activating mutation, p53 inactivat‐
ing mutation and p16 homozygous deletion. The cell line was used 
within 6 months after reexpansion in culture. Cells were cultured in 
RPMI 1640 medium (Sigma Chemical Co., St. Louis, MO) contain‐
ing 10% FBS and maintained at 37°C in a humidified incubator with 
5% CO2 and 95% air. Nab‐paclitaxel was obtained from Celgene 
Corporations (Summit, NJ). Mouse monoclonal anti‐MMP9 antibody 
AB0046 26 was obtained from Gilead Sciences (Foster City, CA).
2.2 | Immunoblot analysis
Tumours obtained from intraperitoneal or subcutaneous xenografts 
were sectioned, snap frozen in liquid nitrogen and stored at −80°C. 
Protein lysates of these tumour sections were prepared by sus‐
pending in lysis buffer and homogenizing using the Bullet Blender 
Homogenizer (Next Generation, Averill Park, NY), and extracts 
were sonicated on ice. Proteins in supernatants were separated by 
SDS‐PAGE and transferred to polyvinylidene difluoride membranes 
(Bio‐Rad, Hercules, CA). The membranes were incubated overnight 
at 4°C with antibodies against vimentin, α‐smooth muscle actin (α‐
SMA), phospho‐stathmin, VEGF, IL‐6 and GAPDH (Cell Signaling 
Technology, Beverly, MA). The membranes were then incubated 
with the corresponding horseradish peroxidase‐conjugated second‐
ary antibodies (Pierce Biotechnologies, Santa Cruz, CA) for 1 hour. 
Protein bands were visualized with an Image360 system after using 
the enhanced chemiluminescence reagent (SignalFire, Cell Signaling) 
and quantitated by densitometry.
2.3 | Immunohistochemistry and 
immunofluorescence
Standard immunohistochemistry protocol was followed to stain the 
tumour tissue sections, as previously described.28 Briefly, tumour 
tissues fixed in 4% paraformaldehyde were dehydrated in a graded 
series of ethanol and deparaffinized with xylene. The tumour tissues 
were then embedded in paraffin and cut into 5 μm sections using mi‐
crotome. The tumour tissue sections were then deparaffinized and 
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rehydrated through graded ethanol followed by heat‐mediated anti‐
gen retrieval using citrate buffer. The tissue sections were incubated 
for 20 minutes in CAS blocking buffer followed by overnight incuba‐
tion at 4°C with 1:200 dilution of primary antibodies against endomu‐
cin (MAB2624, Millipore), collagen I (ab6308, Abcam, Cambridge, MA), 
vimentin (#5741, Cell Signaling) or α‐SMA (C6198, Sigma). The tissue 
sections were washed with PBS and incubated with 1:200 dilution of 
secondary antibody conjugated with Cy3 (Jackson ImmunoResearch 
Laboratories, West Grove, PA) or Alexa Fluor 488 (Life Technologies, 
Grand Island, NY) at room temperature for 40 minutes to visualize 
the antigen. Tissues were then washed and mounted with a mounting 
solution containing 4′,6‐diamidino‐2‐phenylindole (DAPI) (Invitrogen, 
Carlsbad, CA) to visualize nuclei. Fluorescence microscopy was 
used to detect fluorescent signals in five representative high‐power 
field (HPF) per sample using IX81 Olympus microscope and images 
were captured with a Hamamatsu Orca digital camera (Hamamatsu 
Corporation, Bridgewater, NJ) with a DSU spinning confocal unit 
using cellSens Dimension software (Olympus, Center Valley, PA).
2.4 | Luminex assay
Protein analysis of tumour samples from the intraperitoneal xeno‐
grafts was performed by Luminex assay. Briefly, lysates were pre‐
pared using the OMNI bead ruptor homogenizer (OMNI International, 
Kennesaw, GA) in RIPA buffer containing benzonase and protease/
phosphatase inhibitors. Samples were then centrifuged at 14 000 g 
for 10 minutes. The supernatant was transferred to a new tube and 
total protein content was measured. Luminex analysis of these sam‐
ples was performed with rodent MAP 4.0 mouse panel at Ampersand 
Biosciences (Saranac Lake, NY).
2.5 | RNA‐Seq analysis
Gene expression changes in different therapy groups were deter‐
mined by RNA sequencing (RNA‐Seq) of tumour samples from sub‐
cutaneous xenografts. RNA samples isolated from frozen tumours 
using a Qiagen RNAeasy kit (Qiagen, Germantown, MD) were con‐
verted into cDNA libraries using the Illumina TruSeq Stranded mRNA 
sample preparation kit (Illumina #RS‐122‐2103, San Diego, CA), and 
RNA‐Seq was performed (Q2 Solutions, Morrisville, NC). The raw 
fastq files were first run through FastQC to verify the data were of 
high quality and processed using the Expression analysis mRNAv9‐
RSEM pipeline. After removing sequencing adapters and other 
low‐quality bases, the clipped fastq files were aligned to the mouse 
reference genome (build GRCm38) using STAR v2.4. The resulting 
BAM files were fed into the quantification software, RSEM v1.2.14. 
RSEM output the counts of the sequencing reads for each gene and 
sample. After normalization, we performed quality control analyses 
of QC'd, the data set to identify strong batch effects and outlier 
samples using principal component analysis and sample dendro‐
gram. Genes with <1 sequencing read count/106 (CPM) in ≥3 sam‐
ples were removed as low count genes. Generalized linear regression 
in edgeR was used to estimate log2 fold changes and P values. The 
P values were adjusted using the false discovery rate control by fol‐
lowing the Benjamini‐Hochberg procedure. Next, the estimated P 
values of all the genes were converted to z scores using the zScores 
function in the R package gCMAP. The z scores were used to rank 
the list of genes, which was analysed with GSEAPreranked included 
in the Broad GSEA Java tool for Gene set enrichment analysis against 
MSigDB, C2 (curated gene sets), C6 (oncogenic signatures) and C7 
(immunologic signatures) collections.
2.6 | Subcutaneous xenograft studies
All animals were housed in a pathogen‐free facility with access to 
food and water ad libitum. Animal experiments were performed in 
accordance with the Institutional Animal Care and Use Committee 
(IACUC) at the Indiana University School of Medicine (South Bend, 
IN). Female non‐obese diabetic/severe combined immunodeficient 
(NOD/SCID) mice (4‐6 weeks old) were subcutaneously injected 
with AsPC‐1 cells (7.5 × 105) as previously described.29 Two weeks 
after tumour cell injection, all mice had a measurable tumour. Mice 
were then randomized (n = 5 per group) to receive PBS (control), 
nab‐paclitaxel (5 mg/kg, twice a week), gemcitabine (50 mg/kg, 
twice a week) and anti‐MMP9 antibody (50 mg/kg bolus dose on 
day 1, then 20 mg/kg twice a week) via intraperitoneal injection for 
the next 2 weeks. The tumour size was measured twice weekly, and 
tumour volume (V) was calculated using the formula V  =  ½ (Length 
x Width2). Mice were killed after completion of treatment, tumours 
were dissected, weighed and processed for histological, immunoblot 
and RNA‐Seq analysis.
2.7 | Peritoneal dissemination animal studies
Animal survival studies were performed with female NOD/SCID 
mice (4‐6 weeks of age) as previously described.30 Briefly, the mice 
were injected intraperitoneally with AsPC‐1 cells (0.75 × 106 or 
0.65 × 106) and 2 weeks after tumour cell injection, mice were ran‐
domized (n = 5‐7 per group) to receive PBS (control), nab‐paclitaxel 
(5 mg/kg, twice a week), gemcitabine (50 mg/kg, twice a week) and 
anti‐MMP9 antibody (50 mg/kg bolus dose on day 1, then 20 mg/kg 
twice a week) via IP injection for the next 2 or 6 weeks. Animals were 
killed when moribund according to predefined criteria.31,32 Animal 
survival was evaluated from the first day of treatment until death. 
For qualitative assessment of mice in the peritoneal dissemination 
xenograft study, five mice in each therapy group were evaluated for 
jaundice, ascites, tumour burden and metastasis when control mice 
became moribund. The tumours obtained from these mice were pro‐
cessed for Luminex, IHC and Immunoblot analysis.
2.8 | Statistical analysis
Statistical analysis for in vivo tumour growth studies was performed 
by one‐way ANOVA for multiple group comparisons and Student's 
t test for the individual group comparisons. Survival study statis‐
tics were performed with logrank group comparison (GraphPad 
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Prism 6.0, San Diego, CA). We used G*Power 3.1 software for the 
power calculation. With sample size of 5‐7 mice per group, a preset 
α value 0.05 and anticipated change in animal survival or tumour 
size of 40% or more and a standard deviation of 20%, the expected 
power was more than 80% to detect statistically significant differ‐
ences. Luminex assay data were analysed using unpaired t test with 
Welch's correction or Mann‐Whitney rank sum tests (GraphPad 
Prism). P < 0.05 was considered statistically significant.
3  | RESULTS
3.1 | Improvement in animal survival
In an AsPC‐1 PDAC peritoneal dissemination xenograft study with 
14‐day therapy course (injected AsPC‐1 cells 0.75 × 106), median 
animal survival compared to controls (17 days) was increased after 
therapy with NPT (27 days, a 59% increase), Gem (22 days, a 29% 
increase) and NPT+Gem (30 days, a 76% increase). Addition of 
anti‐MMP9 antibody increased survival as follows: NPT+αMMP9 
(30 days, a 76% increase), Gem+αMMP9 (25 days, a 47% increase) and 
NPT+Gem+αMMP9 (33 days, a 94% increase) (Figure 1A). Another 
AsPC‐1 PDAC peritoneal dissemination xenograft study (injected 
AsPC‐1 cells 0.65 × 106) to evaluate the efficacy of maintenance 
therapy revealed that median animal survival (controls: 22 days) was 
increased after 2‐week therapy with NPT+Gem (42 days, a 91% in‐
crease). Combination of 2‐week anti‐MMP9 therapy increased this 
survival to 48 days (a 118% increase). Six‐week maintenance therapy 
with NPT+Gem led to a median survival of 63 days (a 186% increase) 
that was further improved by the addition of 6‐week anti‐MMP9 
antibody therapy to 70 days (a 218% increase). However, a combina‐
tion of 6‐week maintenance therapy of anti‐MMP9 antibody with 
2 weeks of NPT+Gem (49 days) could not establish any survival ben‐
efit over 2‐week NPT+Gem+αMMP9 therapy (48 days) (Figure 1B). 
No significant change in the bodyweight of mice was observed dur‐
ing 2 or 6‐week therapy period, indicating that there was no discern‐
able therapy‐associated toxicity in all therapy groups.
3.2 | Qualitative assessment of tumour‐
associated aspects
In an AsPC‐1 PDAC peritoneal dissemination xenograft study with 
2‐week therapy schedule, qualitative assessment of mice in all ther‐
apy groups was performed when control mice became moribund. 
Evaluation of different tumour‐associated findings revealed that com‐
pared with controls, NPT+Gem therapy led to a significant reduction 
in all aspects observed including jaundice, amount of ascites, tumour 
burden in the pancreas, tumour burden in the stomach, total tumour 
weight, liver metastasis, spleen metastasis and total metastatic bur‐
den. Anti‐MMP9 antibody therapy significantly decreased ascites, 
tumour burden in pancreas and stomach, liver metastasis, spleen 
metastasis and total metastatic burden, as compared with controls. 
However, most of the findings after NPT+Gem+αMMP9 therapy 
were not significantly different from those after NPT+Gem therapy 
alone, except a decrease in tumour burden in the pancreas (Figure 2).
3.3 | Changes in protein expression in tumours from 
intraperitoneal xenografts
Luminex analysis of cytokine or growth factor expression in tu‐
mour lysates from AsPC‐1 PDAC peritoneal dissemination xeno‐
grafts demonstrated NPT+Gem therapy‐induced changes in most 
studied marker proteins including IP‐10, MDC, PAI‐1, MIP‐1b, 
F I G U R E  1   Anti‐MMP9 antibody 
improves animal survival benefits of nab‐
paclitaxel/gemcitabine. Animal survival 
study in the peritoneal dissemination 
model after injecting 0.75 × 106 AsPC‐1 
cells (A) or 0.65 × 106 AsPC‐1 cells (B). 
Two weeks after tumour cell injection in 
NOD/SCID mice, treatment was started 
with nab‐paclitaxel, gemcitabine and 
anti‐MMP9 antibody for 2 wk or 6 wk 
as specified. The curve represents the 
animal survival time from the beginning 
of therapy. Statistical group differences 
in survival time were calculated using 
logrank testing
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IL‐1B and GM‐CSF. An increase in IL28 expression (1.5‐fold, 
P = 0.016) was specifically related to anti‐MMP9 antibody therapy 
as it was significantly higher after both αMMP9 monotherapy and 
NPT+Gem+αMMP9 combination compared to controls or NPT+Gem 
alone (Figure 3).
Anti‐MMP9 antibody related changes in the expression of 
tumourigenic markers were further determined in tumour sec‐
tions from AsPC‐1 PDAC peritoneal xenografts by IHC analysis. 
Endomucin, a vascular endothelial marker, staining for determining 
tumour microvessel density demonstrated a 21% decrease with 
NPT+Gem, 60% decrease with αMMP9 and 65% decrease with 
NPT+Gem+αMMP9 therapy (Figure 4). Further, αMMP9 and 
NPT+Gem+αMMP9 therapy reduced the expression of stromal 
marker protein collagen I by 53% and 66%; and EMT marker pro‐
tein vimentin by 30% and 40% respectively. The other stromal 
marker protein αSMA was significantly decreased by NPT+Gem and 
NPT+Gem+αMMP9 therapy groups by 49% and 64% respectively 
(Figure 4). Furthermore, Immunoblot analysis of lysates from AsPC‐1 
PDAC peritoneal dissemination xenograft study showed decreased 
vimentin expression (>42.5%) and IL‐6 expression (>29%) in αMMP9 
therapy groups. The expression of αSMA was significantly reduced 
by NPT+Gem chemotherapy while it was only slightly decreased by 
αMMP9. VEGF expression was increased by αMMP9 antibody treat‐
ment but not by NPT/Gem therapy (Figure 5).
3.4 | Gene expression changes in the tumour 
microenvironment in subcutaneous xenografts
In an AsPC‐1 subcutaneous xenograft study, compared with con‐
trols, mean tumour weight after 2‐week therapy decreased by 50% 
with NPT+Gem (P = 0.001), 20% with αMMP9 (P = 0.136) and 63% 
with NPT+Gem+αMMP9 (P = 0.0006) (Figure 6A). The difference 
in tumour weight between NPT+Gem and NPT+Gem+αMMP9 did 
not reach statistical significance (Figure 6A). Tumour tissues from 
these subcutaneous xenografts revealed low but detectable levels 
of MMP9 protein in all therapy groups without any significant differ‐
ence in MMP9 expression (Figure 6B). In addition, RNA‐Seq analysis 
to determine numeric gene expression changes in different com‐
partments of the tumour microenvironment showed that αMMP9 
monotherapy, using AB0046 which only inhibits murine MMP9, re‐
sulted in more gene expression changes in the mouse stroma than 
in the human epithelial tumour compartment, compared to other 
F I G U R E  2   Qualitative assessment of tumour‐associated aspects after therapy with anti‐MMP9 antibody and nab‐paclitaxel‐based 
chemotherapy. In an AsPC‐1 PDAC peritoneal dissemination xenograft study with 2‐wk therapy schedule, qualitative assessment of mice 
in all therapy groups was performed when control mice became moribund including jaundice, amount of ascites, tumour burden in the 
pancreas, tumour burden in the stomach, total tumour weight, liver metastasis, spleen metastasis and total metastatic burden
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treatments. In contrast, NPT+Gem+αMMP9 combination therapy 
resulted in greater numbers of changes in gene expression compared 
to the other treatments in the tumour compartment (Figure 6C).
As in prior experiments, no discernable therapy‐related toxicity 
was observed in the subcutaneous xenograft study during the ther‐
apy period as there was no significant change in the mouse body‐
weight in all groups (Figure S1).
4  | DISCUSSION
The hallmarks of pancreatic cancer are an aggressive local growth 
of tumour into surrounding parenchyma, vascular and other peri‐
pancreatic structures, accompanied by rapid metastatic tumour 
progression. Many of these phenomena require degradation of the 
surrounding ECM proteins by MMPs. Recent studies have shown 
an essential role of MMP9 in tumour progression of many solid tu‐
mours including PDAC through modulating stromal tumour micro‐
environment promoting angiogenesis, metastasis, EMT and drug 
resistance.9,10,18,25,33 Given the critical role of tumour stroma in 
PDAC progression, metastasis and therapy resistance, it is sensible 
to explore combination approaches of promising cytotoxic and an‐
tistromal components to accomplish superior therapy benefits. The 
present study was undertaken to determine the target engagement 
of a novel, highly specific anti‐MMP9 antibody within the PDAC tu‐
mour microenvironment, and to define its therapeutic efficacy in 
combination with nab‐paclitaxel‐based cytotoxic chemotherapy in 
pre‐clinical PDAC models.
Peritoneal dissemination is a frequent incidence in PDAC, which 
is associated with a poor prognosis.34 The peritoneal dissemination 
animal survival model used in this study can serve as a relevant 
pre‐clinical model of PDAC as it involves the formation of desmoplas‐
tic stroma and metastasis to liver and other visceral sites.35 Although 
the present study is based on animal experiments using one human 
PDAC cell line AsPC‐1, it is well‐established and a good represen‐
tative of clinical PDAC in terms of oncogenic mutations (KRAS, 
p53 and p16), aggressiveness and chemoresistance. In the present 
study, a modest but reproducible and at times significant effect of 
anti‐MMP9 antibody to improve survival benefits of NPT‐based 
chemotherapy regimens correlates well with its down‐regulatory 
F I G U R E  3   Luminex analysis of cytokine and growth factor expression after treatment with anti‐MMP9 antibody and nab‐paclitaxel‐
based chemotherapy. The Luminex assay was performed in tumour lysates from AsPC‐1 PDAC intraperitoneal xenografts. The red lines 
denote the lowest limit of detection for the analysis. The data were analysed using unpaired t test with Welch's correction or Mann‐Whitney 
rank sum tests (GraphPad Prism)
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effects on stromal and EMT markers such as endomucin, collagen I 
and vimentin. Furthermore, increased levels of IL28 are quite likely a 
specific effect of anti‐MMP9 therapy that might also be partaking in 
extending survival benefits of NPT‐based chemotherapy, because a 
previous study demonstrated an antitumour impact of IL28 against 
human lung cancer cells.36 Anti‐MMP9 antibody therapy survival 
F I G U R E  4   IHC analysis of stromal and EMT markers after treatment with anti‐MMP9 antibody and nab‐paclitaxel‐based chemotherapy. 
Tumour tissue sections obtained from the AsPC‐1 PDAC peritoneal xenograft study were analysed by IHC. Tissue sections were 
immunostained with antibodies to determine tumour vasculature (endomucin), stromal markers (collagen‐I, SMA) and EMT marker (vimentin) 
and slides were photographed under a fluorescent microscope. Positive staining was calculated within a microscopic HPF in a blinded 
manner and the data are expressed as the mean ± SD
F I G U R E  5   Immunoblot analysis of stromal and EMT markers after treatment with anti‐MMP9 antibody and nab‐paclitaxel‐based 
chemotherapy. Protein lysates of tumours obtained from intraperitoneal xenografts were separated by SDS‐PAGE and the membranes were 
incubated with antibodies against vimentin, α‐SMA, VEGF, IL‐6, phospho‐stathmin and GAPDH. A, Protein bands were visualized with an 
Image360 system after using the enhanced chemiluminescence reagent. B, The intensity of bands was quantitated by densitometry and is 
represented in the bar graph after normalizing values with GAPDH expression
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benefits correlated well with the qualitative assessment of mice in 
terms of jaundice, ascites, pancreatic tumour mass and metastatic 
burden. Decreased tumour angiogenesis as observed by reduced 
tumour microvessel density in peritoneal dissemination xenografts 
after anti‐MMP9 antibody therapy may be unrelated to the increase 
in VEGF expression. This likely reflects a stromal response that 
stands in contrast to some published reports indicating a decrease in 
VEGF by MMP9 inhibition.37 In this model system, we suspect that 
the VEGF increase is a compensatory mechanism due to the specific 
antiangiogenic effect of anti‐MMP9 therapy.
Subcutaneous xenograft studies to verify target (MMP9) ex‐
pression and evaluate therapy effects in different compartments 
of the tumour microenvironment demonstrated maximum gene 
expression changes within the tumour stroma by anti‐MMP9 anti‐
body additionally supporting its antistromal activity in the PDAC 
tumour microenvironment. However, in contrast to the peritoneal 
dissemination tumour model, the efficacy of anti‐MMP9 antibody 
in the subcutaneous was reduced. This can likely be attributed 
to the absence of tumour progression steps leading to metasta‐
sis in subcutaneous xenografts, and to possible differences in the 
desmoplastic reaction between the two models that affect the ef‐
ficacy of anti‐MMP9 stromal targeting. In this context, we do con‐
sider the peritoneal dissemination tumour model more clinically 
relevant to PDAC compression compared with the subcutaneous 
tumour model.
Due to the multifactorial effects of nab‐paclitaxel‐based chemo‐
therapy and anti‐MMP9 antibody on PDAC progression, it is likely 
that specific molecular mechanisms of these two regimens regulate 
the potential of combination therapy. We have previously observed 
a correlation between antitumour benefits of nab‐paclitaxel‐
based chemotherapy and its antimitotic and antistromal effects in 
PDAC.29,38 The advantages of nab‐paclitaxel‐based chemotherapy 
can likely be attributed to better drug distribution, bioavailability, 
tumour penetration and higher retention of itself and other drugs 
used in combination. Although the exact mechanisms for the aug‐
mentation of nab‐paclitaxel‐based chemotherapy by anti‐MMP9 an‐
tibody remain indistinct, these can be correlated with normalization 
or reduction in tumour vasculature, depletion of tumour stroma en‐
hancing bioavailability of chemotherapy drugs and direct inhibition 
of ECM degradation leading to antimetastatic effects.26,39,40
F I G U R E  6   Effect of anti‐MMP9 antibody and nab‐paclitaxel‐based chemotherapy in AsPC‐1 subcutaneous xenografts. A, Mean tumour 
weight was calculated from final day tumour weights in each group and presented as a Box plot (B), Quantitative Western blot analysis of 
tumour tissues for MMP9 protein expression using anti‐MMP9 antibody and secondary antibody conjugated with fluorescent dye (C), RNA‐
Seq analysis of tumour tissues for gene expression changes in different compartments of the tumour microenvironment
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Multiple mechanisms are involved in PDAC growth and progres‐
sion including an increase in tumour cell proliferation, differentia‐
tion, invasion, migration, angiogenesis and EMT. Therefore, a more 
effective therapeutic regimen would likely impact on most of these 
pro‐tumourigenic mechanisms with manageable toxicity. Based on 
the negative impact of anti‐MMP9 antibody in the pre‐clinical PDAC 
models in terms of tumour stroma, metastasis and EMT, our data sup‐
port the possible advantages of anti‐MMP9 antibody therapy in PDAC 
patients with localized non‐metastatic disease. Importantly, clinical 
failure of early broad‐spectrum MMP inhibitors was correlated with 
a large number of patients with metastatic disease.12,13,25 Recently, 
anti‐MMP9 antibody has also been shown to promote antitumour im‐
munity by activating T cells in the gastric cancer microenvironment.41 
Overall, the present study demonstrates that with an anti‐MMP9 an‐
tibody, direct enhancement of PDAC cytotoxic therapy is not high but 
the specific mechanistic footprint of MMP9 inhibition should be ex‐
plored for its contribution benefit to combinations with antivascular, 
other antistromal and immune‐based therapy.
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